Search - tctmd.com

Displaying 61 - 80 of 204

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for August 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

September 04, 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

August 20, 2018

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

June 25, 2018

Spin to Win: Results From Late Breaking Meeting Trials Often Overstated

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

May 15, 2018

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

Tool Predicts Stroke Risk in Patients With Systolic Dysfunction After MI

News Daily News

Tool Predicts Stroke Risk in Patients With Systolic Dysfunction After MI

February 12, 2018

Could NOACs Have a Role for Secondary Prevention After STEMI?

News Daily News

Could NOACs Have a Role for Secondary Prevention After STEMI?

February 08, 2018

TCTMD’s Top 10 Most Popular Stories for January 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

January 31, 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

News Conference News ISC 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

January 25, 2018

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

January 02, 2018

The Biggest News of 2017: TCTMD’s Top 10

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

January 01, 2018

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Presentation AHA 2017

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Presenter: Andre Lamy

November 15, 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

News Conference News AHA 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

Michael O'Riordan

November 13, 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

November 09, 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.